Resverlogix Corp.
ZHCLF
Rank in Stocks
#26924
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Share Price
$0.0004
Last synced: 2026-11-13
Market Cap
$17.30M
Change (1 day)
0.00%
Change (1 year)
-99.20%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Resverlogix Corp. (ZHCLF)
Category
Healthcare
EPS for Resverlogix Corp. (ZHCLF)
EPS as of July 2026 TTM: $-0.06
According to Resverlogix Corp.'s latest financial reports, its current EPS (TTM) is $-0.06. At the end of 2025 the company had an EPS of $-0.05, an increase over its 2024 EPS of $-0.07.
EPS history for Resverlogix Corp. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.06 | 14.20% |
| 2025 | $-0.05 | -31.19% |
| 2024 | $-0.07 | -26.03% |
| 2023 | $-0.09 | 64.35% |
| 2022 | $-0.06 | 11.43% |
| 2021 | $-0.05 | 51,500.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | -99.85% |
| 2018 | $-0.07 | 16.82% |
| 2017 | $-0.06 | -32.57% |
| 2016 | $-0.08 | -4.05% |
| 2015 | $-0.09 | -68.00% |
| 2014 | $-0.27 | 22.73% |
| 2013 | $-0.22 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | 1,458.67% |
US
|
|
| $15.66 | -27,525.57% |
US
|
|
| $-7.07 | 12,281.79% |
US
|
|
| $-5.29 | 9,164.45% |
AU
|
|
| $12.73 | -22,398.07% |
BE
|
Questions about Resverlogix Corp.'s earnings per share (EPS)
What is Resverlogix Corp.'s earnings per share (EPS)?
Resverlogix Corp.'s earnings per share (EPS) over the last twelve months is $-0.06, as of Jul 2026.
What was Resverlogix Corp.'s earnings per share (EPS) in 2025?
In 2025, Resverlogix Corp.'s earnings per share (EPS) was $-0.05, compared with $-0.07 in 2024.
How has Resverlogix Corp.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Resverlogix Corp.'s earnings per share (EPS) was highest in 2020 (0.00) and lowest in 2023 ($-0.09).
How does Resverlogix Corp.'s earnings per share (EPS) compare with similar companies?
Resverlogix Corp.'s earnings per share (EPS) ($-0.06) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.